Using PET-CT compared with CT before surgery for potentially resectable liver metastases from colorectal cancer may not significantly alter surgical management.
Use of PET-CT before surgery among patients with potentially resectable hepatic metastases from colorectal cancer does not significantly change the surgical treatment, according to a study published in JAMA.
Researchers from Canada sought to determine if there was value in imaging prior to surgery for colorectal cancer, and if the use of imaging would result in avoidance of noncurative surgery. According to the study, approximately 50 percent of patients have cancer spread to the liver. Some patients with liver metastases are candidates for surgery to have the cancer removed; however, previously unidentified occult metastases discovered during the time of surgery can render the operation noncurative. The study determined whether PET-CT imaging could identify patients with occult metastases prior to surgery, and therefore avoid noncurative surgery in these patients.
The multi-center randomized trial included adult patients with colorectal cancer who:
• Were treated with surgery
• Had resectable metastases based on CT scans of the chest, abdomen, and pelvis within the previous 30 days
• Had a clear colonoscopy within the previous 18 months
A total of 263 patients underwent PET-CT scans, 134 controls underwent CT only. While there was new information for 111 of the PET-CT patients (62 were classified as negative and 49 had abnormal or suspicious lesions), there was a change in surgical management for only 21:
• Seven (2.7 percent) did not undergo laparotomy
• Four (1.5 percent) underwent more extensive hepatic surgery
• Nine (3.4 percent) underwent additional organ surgery
• One patient underwent surgery to open the abdominal cavity, but hepatic surgery was not performed and the cavity was closed
Liver resection rates were similar for both groups: 91 percent of patients in the PET-CT group and 92 percent of the control group. Follow-up of 36 months showed an estimated mortality rate of 11.13 events/1,000 person-months for the PET-CT group and 12.71 events/1,00 person-months for the control group.
The researchers concluded that use of PET-CT in this patient group did not frequently change surgical management so the value for the examinations is questionable.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Predicting Diabetes on CT Scans: What New Research Reveals with Pancreatic Imaging Biomarkers
March 25th 2025Attenuation-based biomarkers on computed tomography (CT) scans demonstrated a 93 percent interclass correlation coefficient (ICC) agreement across three pancreatic segmentation algorithms for predicting diabetes, according to a study involving over 9,700 patients.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.